US FTC challenges more than 300 'junk listings' for diabetes, weight loss, asthma, COPD drug patents
MLex Summary: The US Federal Trade Commission announced it has expanded its campaign against pharmaceutical manufacturers’ improper or inaccurate listing of patents in the Food and Drug Administration’s Orange Book, disputing...To view the full article, register now.
Already a subscriber? Click here to view full article